Evaxion Biotech A/S (EVAX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Evaxion (EVAX) Q1 2026: 86% Immunogenicity Rate in EVX01 Underscores AI Vaccine Platform Scalability
June 17, 2026
-
Evaxion (EVAX) Q2 2025: $4.1M Equity Boost Secures Cash Runway Past Key MSD Milestone
June 16, 2026
-
Evaxion (EVAX) Q3 2025: MSD Option Adds $7.5M, Extends Runway to 2027 as Pipeline Advances
June 16, 2026
-
Evaxion (EVAX) Q4 2025: Cash Runway Extended to 2027 as AI Immunology Drives Pipeline Momentum
June 15, 2026